Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRICLOS is an oral small-molecule tablet in pre-launch development by Sanofi under NDA review. The mechanism of action, indication(s), and therapeutic class have not been disclosed in available data. Patient population and clinical utility cannot be determined without indication information.
Pre-Launch
Early-stage asset with commercial team mobilization ongoing; launch readiness and market access roles actively staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Wound Healing and Bacterial Adherence With Triclosan-Coated Sutures After Mandibular Impacted Third Molar Surgery
Started Oct 2025
Career Relevance
TRICLOS is a pre-launch asset with zero currently linked job postings, indicating early commercial team formation phase. Career opportunity exists in launch infrastructure roles across commercial, medical affairs, and market access functions.
Brand Manager
Worked on TRICLOS at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.